GleamWall
中文EN

APMD Apnimed, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1745648 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets23.3%
Debt / equity0.14x
Current ratio9.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$2.48M$12.08M—$8.80M$17.11M—
R&D expense$11.81M$9.90M—$9.75M$15.97M—
SG&A expense$22.63M$12.67M—$6.04M$5.35M—
Operating income-$32.20M-$11.70M—-$8.98M-$5.94M—
Pretax income-$29.52M$40.73M—-$8.72M-$5.63M—
Income tax—$0——$0—
Net income-$29.52M$125.94M$67.72M-$10.91M-$69.47M-$28.65M
EBITDA-$32.20M——-$8.98M——
EPS (basic)-1.05——-2.29——
EPS (diluted)-1.05——-2.29——
Weighted avg. shares (diluted)28.02M32.35M—4.77M4.75M—
Balance sheet
Cash & equivalents$351.83M$172.80M—$56.62M——
Receivables$588,000$690,000————
Current assets$360.96M$184.77M————
PP&E, net$46,000$53,000————
Total assets$371.49M$195.46M————
Current liabilities$36.96M$35.58M————
Long-term debt$39.06M$40.27M————
Total debt$39.06M$40.27M————
Total liabilities$86.73M$125.70M————
Shareholders' equity$284.76M-$176.18M-$304.12M-$354.64M-$345.03M-$276.46M
Net debt-$312.77M-$132.54M————
Shares outstanding41.63M4.80M————
Cash flow statement
Operating cash flow-$21.18M——-$17.27M——
Investing cash flow$0——$0——
Financing cash flow$200.70M——$35.07M——
Depreciation & amortization$7,000——$8,000——
Stock-based compensation$6.27M——$1.23M——

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.